Is Sprycel Chemotherapy?
No, Sprycel (dasatinib) is not chemotherapy. It's a targeted tyrosine kinase inhibitor that blocks specific proteins (BCR-ABL, SRC family kinases) driving chronic myeloid leukemia (CML) cell growth.[1] Chemotherapy uses cytotoxic drugs that kill rapidly dividing cells indiscriminately, often causing widespread side effects like hair loss and nausea.
How Does Sprycel Work Differently?
Sprycel targets cancer cells genetically—binding to mutated enzymes in Philadelphia chromosome-positive CML—while sparing most healthy cells. Approved by the FDA in 2006 for CML and acute lymphoblastic leukemia (ALL), it produces deeper, faster responses than traditional chemo in these cases.[2]
Common Side Effects Compared to Chemo
Patients report pleural effusion (fluid around lungs), diarrhea, and fatigue with Sprycel, but less hair loss or severe myelosuppression than chemo.[3] Long-term use requires monitoring for pulmonary hypertension or QT prolongation.
Who Makes Sprycel and What's the Cost?
Bristol Myers Squibb manufactures Sprycel. Monthly costs range $10,000–$15,000 without insurance, though patient assistance programs exist.[4] Generic dasatinib entered the U.S. market in 2025 after patent expiry.
When Does the Patent Expire?
Key U.S. patents on Sprycel expired December 31, 2024, allowing generics. Check DrugPatentWatch.com for litigation details and remaining pediatric exclusivities.[5]
[1] FDA Label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021986s053lbl.pdf
[2] NCCN Guidelines for CML (v.2024)
[3] Sprycel Prescribing Information
[4] GoodRx pricing data (2024)
[5] DrugPatentWatch.com